See more : Motorola Solutions, Inc. (0K3H.L) Income Statement Analysis – Financial Results
Complete financial analysis of Cogent Biosciences, Inc. (COGT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cogent Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- PT Waskita Beton Precast Tbk (WSBP.JK) Income Statement Analysis – Financial Results
- Exxon Mobil Corporation (XOM.NE) Income Statement Analysis – Financial Results
- Inspur Software Co., Ltd. (600756.SS) Income Statement Analysis – Financial Results
- CareCloud, Inc. (MTBCP) Income Statement Analysis – Financial Results
- Santos Limited (SSLZY) Income Statement Analysis – Financial Results
Cogent Biosciences, Inc. (COGT)
About Cogent Biosciences, Inc.
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 7.87M | 22.50M | 9.73M | 8.36M | 6.36M | 2.99M |
| Cost of Revenue | 3.59M | 5.88M | 147.00K | 25.74K | 43.71K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -3.59M | -5.88M | -147.00K | 7.85M | 22.46M | 9.73M | 8.36M | 6.36M | 2.99M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 99.67% | 99.81% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 170.17M | 121.63M | 55.91M | 72.65M | 43.71M | 38.29M | 29.83M | 21.99M | 6.85M |
| General & Administrative | 34.38M | 26.21M | 19.64M | 17.42M | 10.97M | 7.45M | 4.68M | 3.43M | 2.73M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 34.38M | 26.21M | 19.64M | 17.42M | 10.97M | 7.45M | 4.68M | 3.43M | 2.73M |
| Other Expenses | 0.00 | 3.61M | 2.81M | -246.00K | 78.00K | 320.00K | 274.00K | 681.00K | 0.00 |
| Operating Expenses | 208.13M | 147.84M | 75.55M | 90.07M | 54.68M | 45.74M | 34.51M | 25.43M | 9.58M |
| Cost & Expenses | 208.13M | 147.84M | 75.55M | 90.07M | 54.68M | 45.74M | 34.51M | 25.43M | 9.58M |
| Interest Income | 13.08M | 3.99M | 467.00K | 144.00K | 267.00K | 1.15M | 386.00K | 265.00K | 0.00 |
| Interest Expense | 0.00 | 3.99M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.27M | 5.88M | 147.00K | 720.00K | 1.29M | 1.32M | 1.17M | 830.00K | 179.00K |
| EBITDA | -205.86M | -134.36M | -75.40M | -34.57M | -30.89M | -34.68M | -24.98M | -18.24M | -6.41M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -1,139.52% | -143.02% | -356.32% | -298.82% | -287.02% | -214.77% |
| Operating Income | -208.13M | -147.84M | -75.55M | -82.20M | -32.18M | -36.01M | -26.15M | -19.07M | -6.59M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -1,044.33% | -143.02% | -369.89% | -312.82% | -300.08% | -220.76% |
| Total Other Income/Expenses | 15.72M | 7.60M | 3.28M | 7.39M | 345.00K | 1.47M | 660.00K | 946.00K | 0.00 |
| Income Before Tax | -192.41M | -140.24M | -72.27M | -74.81M | -31.83M | -34.53M | -25.49M | -18.12M | -6.59M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -950.43% | -141.49% | -354.76% | -304.93% | -285.19% | -220.76% |
| Income Tax Expense | 0.00 | -7.60M | -467.00K | -8.36M | -1.56M | 1.47M | -386.00K | -265.00K | 0.00 |
| Net Income | -192.41M | -132.64M | -71.81M | -66.45M | -30.27M | -34.53M | -25.49M | -18.12M | -6.59M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -844.25% | -134.55% | -354.76% | -304.93% | -285.19% | -220.76% |
| EPS | -2.42 | -2.26 | -1.85 | -6.00 | -3.97 | -5.55 | -3.45 | -3.10 | -1.13 |
| EPS Diluted | -2.42 | -2.26 | -1.85 | -6.00 | -3.97 | -5.55 | -3.45 | -2.45 | -0.89 |
| Weighted Avg Shares Out | 79.66M | 58.74M | 38.73M | 11.08M | 7.62M | 6.22M | 7.40M | 5.86M | 5.86M |
| Weighted Avg Shares Out (Dil) | 79.66M | 58.74M | 38.73M | 11.08M | 7.62M | 6.22M | 7.40M | 7.40M | 7.40M |
Cogent Biosciences to Present SUMMIT Part 1b Data with Bezuclastinib in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2024 AAAAI Annual Meeting
Company to Host Virtual Investor Webcast on Friday, February 23 at 8:00 a.m. ET Company to Host Virtual Investor Webcast on Friday, February 23 at 8:00 a.m. ET
Cogent Biosciences Announces Planned 2024 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics
WALTHAM, Mass. and BOULDER, Colo., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today highlighted the company's key 2024 milestones ahead of its presentation at...
Cogent Biosciences Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass. and BOULDER, Colo., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins, President and Chief Executive Officer, will present at...
Cogent Biosciences stock drops as analysts see tough competition for mastocytosis treatment
Cogent Biosciences Inc. shares COGT, -1.48% fell more than 30% premarket on Monday after the company over the weekend released clinical trial data on its lead drug candidate that failed to outshine potential competitors, in analysts' view. In a trial...
Cogent Biosciences Announces Positive Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
56% ORR in TKI-naïve patients, including 86% ORR by PPR criteria and 100% ORR in APEX patients treated at 100 mg BID with exposures consistent with go-forward dose
Cogent Biosciences Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)
Rapid and ongoing improvement in patient symptoms, with 57% median best improvement on MC-QoL and 78% of patients reporting ≥1 point improvement on PGIS by week 20
Cogent Biosciences Presents New Preclinical Data Highlighting Potential Best-in-Class Potency and Selectivity of ErbB2 and PI3Kα inhibitor programs at the San Antonio Breast Cancer Symposium
Novel EGFR-sparing, brain-penetrant ErbB2 inhibitor demonstrates superior efficacy profile reaching 80% brain penetrance with potent coverage of key mutations inadequately addressed by currently approved therapies
Cogent Biosciences Announces Poster Presentations at Upcoming San Antonio Breast Cancer Symposium
WALTHAM, Mass. and BOULDER, Colo., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced two poster presentations at the upcoming 2023 San Antonio Breast Cancer...
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2023 Financial Results
SUMMIT and APEX clinical presentations planned for 2023 ASH Annual Meeting; SUMMIT NonAdvSMdata selected for oral presentation
Cogent Biosciences Presents Preclinical Data Highlighting Precision Oncology Pipeline at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
– Novel selective and reversible FGFR2 inhibitor exhibits strong potency across key primary and resistance driver mutations with potential advantages over covalent approaches –
Source: https://incomestatements.info
Category: Stock Reports